Stock listing

LS Exchange:A2AP4F Revive Therapeutics Ltd. Aktie

German listing (LS Exchange) of Revive Therapeutics Ltd. · home listing CSE:RVV

Follow Revive Therapeutics Ltd. into a list and get an email when it puts out news.

Home listing price · CSE:RVV

$0.01 CAD 0.00 (0.0%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, CSE:RVV

Past year 0.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.01 – $0.01 CADNov 20, 2026
Volume
1.55M sharesNov 20, 2026
Market cap
$4.45M CADAt the close on Nov 20, 2026 · price × 444.6M shares outstanding
52-week range
$0.0050 – $0.08 CADLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$3,708 CADMedian day 60,830 shares · 4 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
Revive Therapeutics Ltd. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
CSE:RVV · Home$0.01 CAD0.00 (0.0%)1,548,000$0.01$0.01$0.01$0.01Close on Nov 20, 2026
OTC:RVVTF$0.0070 USD-0.0001 (-1.4%)179,500$0.0076$0.0076$0.0064$0.0071Close on Nov 20, 2026
Frankfurt:31R€0.0010 EUR-0.0010 (-50.0%)—€0.0110€0.0120€0.0010€0.0020Close on Nov 19, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · CSE:RVV · CAD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.010.000.0%$0.01$0.01$0.011,548,000
$0.01-0.005-33.3%$0.015$0.015$0.012,306,226
$0.0150.000.0%$0.015$0.015$0.01536,004
$0.0150.000.0%$0.015$0.015$0.011,171,075
$0.0150.000.0%$0.015$0.015$0.0150
$0.015-0.005-25.0%$0.015$0.015$0.01510,000
$0.020.000.0%$0.02$0.02$0.0250,000
$0.020.000.0%$0.02$0.02$0.020
$0.02+0.005+33.3%$0.02$0.02$0.025,018
$0.015-0.005-25.0%$0.02$0.02$0.01511,700
$0.02+0.005+33.3%$0.02$0.02$0.0225,000
$0.015-0.005-25.0%$0.015$0.015$0.015135,964
$0.02+0.005+33.3%$0.02$0.02$0.022,864
$0.015-0.005-25.0%$0.015$0.015$0.0158,100
$0.020.000.0%$0.015$0.02$0.01543,871
$0.02+0.005+33.3%$0.02$0.02$0.02212,393
$0.015-0.005-25.0%$0.025$0.025$0.01561,940
$0.020.000.0%$0.02$0.02$0.0281,000
$0.020.000.0%$0.02$0.02$0.0298,000
$0.020.000.0%$0.02$0.02$0.0288,800
$0.020.000.0%$0.02$0.025$0.02355,859
$0.02-0.005-20.0%$0.02$0.02$0.02677,356
$0.0250.000.0%$0.025$0.025$0.0250
$0.0250.000.0%$0.025$0.025$0.0251,654
$0.0250.000.0%$0.025$0.025$0.02515,000
$0.025-0.005-16.7%$0.025$0.025$0.02510,000
$0.03+0.005+20.0%$0.03$0.03$0.033,260
$0.025-0.005-16.7%$0.025$0.025$0.025113,000
$0.03+0.005+20.0%$0.03$0.03$0.036,664
$0.025-0.005-16.7%$0.025$0.025$0.02560,830
$0.03+0.005+20.0%$0.03$0.03$0.03204,725
$0.025-0.005-16.7%$0.025$0.025$0.02513,800
$0.030.000.0%$0.03$0.03$0.03111,515
$0.03+0.005+20.0%$0.03$0.03$0.039,496
$0.0250.000.0%$0.025$0.025$0.0238,930
$0.0250.000.0%$0.025$0.025$0.0256,000
$0.025-0.005-16.7%$0.025$0.025$0.02132,000
$0.03+0.01+50.0%$0.025$0.03$0.025652,865
$0.020.000.0%$0.02$0.02$0.02104,580
$0.02-0.005-20.0%$0.02$0.02$0.026,110
$0.0250.000.0%$0.025$0.025$0.0250
$0.025+0.005+25.0%$0.025$0.025$0.02514,000
$0.02-0.005-20.0%$0.025$0.025$0.02124,358
$0.025+0.005+25.0%$0.02$0.025$0.026,839
$0.020.000.0%$0.02$0.02$0.02195,000
$0.020.000.0%$0.02$0.025$0.02105,720
$0.020.000.0%$0.02$0.02$0.02262,176
$0.02+0.005+33.3%$0.02$0.02$0.02422,160
$0.015-0.01-40.0%$0.025$0.025$0.0151,850,378
$0.0250.000.0%$0.025$0.025$0.0251,080
$0.0250.000.0%$0.025$0.025$0.025198,480
$0.0250.000.0%$0.025$0.025$0.02529,098
$0.0250.000.0%$0.025$0.025$0.025132,100
$0.025-0.005-16.7%$0.025$0.025$0.02526,500
$0.03+0.005+20.0%$0.03$0.03$0.036,070
$0.025+0.005+25.0%$0.025$0.025$0.0252,000
$0.02-0.005-20.0%$0.025$0.025$0.0271,900
$0.0250.000.0%$0.025$0.025$0.02536,384
$0.0250.000.0%$0.025$0.025$0.02531,000
$0.025-0.005-16.7%$0.025$0.025$0.025363,000
$0.03+0.005+20.0%$0.025$0.03$0.02562,739
$0.0250.000.0%$0.03$0.03$0.025589,200
$0.0250.000.0%$0.025$0.025$0.025267,100
$0.025-0.005-16.7%$0.025$0.025$0.025268,000
$0.03+0.005+20.0%$0.03$0.03$0.03132,000
Ticker
LS Exchange:A2AP4F
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
LS Exchange
Currency
EUR

What changed lately

Latest news

All Revive Therapeutics Ltd. news

Revive Therapeutics Ltd. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
8 in the last 12 months · 23 in all · newest Sep 15, 2026 · oldest 2014
Decks
36 decks · latest August 2026

Where Revive Therapeutics Ltd. is listed

ListingExchangeCountryCurrency
CSE:RVV · Home listingCSECanadaCAD
OTC:RVVTFOTCUnited StatesUSD
gettex:31RgettexGermanyEUR
Cboe Canada:RVVCboe CanadaCanadaCAD
LS Exchange:A2AP4F · This pageLS ExchangeGermanyEUR
Frankfurt:31RFrankfurtGermanyEUR
Lang & Schwarz:A2AP4FLang & SchwarzGermanyEUR
Munich:31RMunichGermanyEUR

Valuation

Statements: 4 quarters to Mar 31, 2026 · price Nov 20, 2026

Enterprise value
$4.50M CAD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P/TSX Composite
0.56

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Revive Therapeutics Ltd. · CSE:RVVUS$3.10MUS$3.14Mn/an/an/an/an/an/a0.56
Xenetic Biosciences, Inc. · NASDAQ:XBIOUS$3.28M−US$2.53Mn/a−0.8×n/a0.7×−123.7%0.0×1.46
Aprea Therapeutics, Inc. · NASDAQ:APREUS$3.25M−US$34.60Mn/an/an/a0.1×n/a0.0×0.73
Spago Nanomedical AB · OMXSTO:SPAGOUS$3.21MUS$22,113n/a5.6×n/a1.0×n/a0.0×n/a
Kiora Pharmaceuticals, Inc. · NASDAQ:KPRXUS$3.19M−US$12.81Mn/a−12.8×n/a0.2×n/a0.0×1.54
Azitra Inc · AMEX:AZTRUS$3.13M−US$618,677n/an/an/a0.7×n/a0.0×0.60
NuCana plc · NASDAQ:NCNAUS$3.12M−US$21.39Mn/an/an/a0.1×n/a0.0×1.58
Skye Bioscience, Inc. · NASDAQ:SKYEUS$3.10M−US$1.71Mn/an/an/a2.3×n/a0.0×0.85
Creative Medical Technology Holdings, Inc. · NASDAQ:CELZUS$3.06M−US$3.79Mn/a−1,263×n/a0.4×n/a0.0×1.53
Oncology Pharma Inc. · OTC:ONPHUS$3.04Mn/an/an/an/an/an/an/a1.62
Imunon, Inc. · NASDAQ:IMNNUS$3.00MUS$5.90Mn/an/an/a1.1×n/a2.6×0.57
Median of the othersUS$3.13M−US$2.53M−6.8×0.7×−123.7%0.0×1.46

Team and board

Officers

OfficerRole
Michael FrankChairman and Chief Executive Officer
Carmelo MarrelliChief Financial Officer

Board

DirectorRole
Michael FrankChairman and Chief Executive Officer
Andrew LindzonDIRECTOR
Christian ScovennaDIRECTOR
Joshua HermanDIRECTOR
William JacksonDIRECTOR

Events

QuarterResultsShare move
Q3 2023May 30, 2023 · After close−9.1%
Q2 2023Feb 27, 2023 · After close−3.7%
Q1 2023Oct 27, 2022 · After close+2.2%
Q3 2022May 29, 2022 · After close+12.1%
Q2 2022Feb 28, 2022 · After close−10.0%
Q1 2022Oct 25, 2021 · After close+4.4%
Quarter to Mar 31, 2021May 31, 2021 · After close−2.1%
Quarter to Dec 31, 2020Mar 1, 2021 · After close−4.1%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (August 2026)Investor deck16 slidesAugust 2026
Investor Presentation (March 2026)Investor deck13 slidesMarch 2026
Investor Presentation (February 2026)Investor deck13 slidesFebruary 2026
Investor Presentation (May 2025)Investor deck15 slidesMay 2025
Investor Presentation (February 2025)Investor deck15 slidesFebruary 2025
Investor Presentation (September 2024)Investor deck15 slidesSeptember 2024
Investor Presentation (May 2024)Investor deck16 slidesMay 2024
Investor Presentation (February 2024)Investor deck16 slidesFebruary 2024
Investor Presentation (February 2024)Investor deck16 slidesFebruary 2024
Investor Presentation (February 2024)Investor deck16 slidesFebruary 2024
All 36 decks
DeckKindSlidesDate
Investor Presentation (November 2023)Investor deck16 slidesNovember 2023
Investor Presentation (July 2023)Investor deck15 slidesJuly 2023
Fact Sheet (March 2023)Fact sheet2 slidesMar 24, 2023
Investor Presentation (March 2023)Investor deck15 slidesMarch 2023
Investor Presentation (February 2023)Investor deck17 slidesFebruary 2023
Investor Presentation (October 2022)Investor deck17 slidesOctober 2022
Investor Presentation (August 2022)Investor deck17 slidesAugust 2022
Investor Presentation (April 2022)Investor deck17 slidesApril 2022
Investor Presentation (February 2022)Investor deck17 slidesFebruary 2022
Fact Sheet (February 2022)Fact sheet2 slidesFebruary 2022
Investor Presentation (January 2022)Investor deck17 slidesJanuary 2022
Investor Presentation (November 2021)Investor deck18 slidesNovember 2021
Investor Presentation (October 2021)Investor deck18 slidesOctober 2021
Investor Presentation (September 2021)Investor deck18 slidesSeptember 2021
Investor Presentation (July 2021)Investor deck18 slidesJuly 2021
Investor Presentation (March 2021)Investor deck18 slidesMarch 2021
Investor Presentation (March 2021)Investor deck18 slidesMarch 2021
Investor Presentation (February 2021)Investor deck18 slidesFebruary 2021
Investor Presentation (January 2021)Investor deck18 slidesJanuary 2021
Investor Presentation (December 2020)Investor deck18 slidesDecember 2020
Investor Presentation (November 2020)Investor deck17 slidesNovember 2020
Investor Presentation (April 2020)Investor deck17 slidesApril 2020
Investor Presentation (April 2020)Investor deck17 slidesApril 2020
Investor Presentation (March 2020)Investor deck17 slidesMarch 2020
Investor Presentation (March 2020)Investor deck16 slidesMarch 2020
Investor Presentation (February 2020)Investor deck23 slidesFebruary 2020

Open Decks

Financings

RaiseDateIn US dollars
Private placement of units
Tranche closed: C$246,920 raised · C$0.032 a unit · 1 warrant at C$0.05 for 36 months
Use of proceeds: Primarily working capital
Jul 15, 2026US$175,756
Private placement of units
Announced: up to C$1M · C$0.032 a unit · 1 warrant at C$0.05 for 36 months
Use of proceeds: Working capital
Jun 26, 2026US$704,920
Private placement of units
Tranche closed: C$91,400 in the latest tranche · C$0.021 a unit · 1 warrant at C$0.05 for 36 months · free to trade Jan 19, 2026
Use of proceeds: Working capital and payment of certain trade payables
Sep 19, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in CAD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0000000000
Research and development144.8K1.11M3.58M15.2M6.70M455.1K124.8K373.2K408.2K
Selling, general and administrative1.40M2.18M1.94M2.68M11.9M3.20M1.19M1.47M1.26M873.2K
Operating income-1.65M-5.61M-6.39M-17.9M-20.3M-5.34M-1.34M-1.84M-1.67M-2.75M
Depreciation and amortization24833043057877528.3K3.20K3.13K3.57K6.22K
EBITDA-1.65M-5.61M-6.39M-17.9M-20.3M-5.31M-1.34M-1.84M-1.67M-2.74M
Interest expense63220.1K44.0K63.4K79.0K87.7K0000
Income before tax-11.0M-5.62M-6.32M-17.8M-20.1M-5.38M-1.34M-1.79M-1.62M-2.74M
Net income-11.0M-5.62M-6.32M-17.8M-20.1M-5.38M-1.34M-1.79M-1.62M-2.74M
Earnings per share, basic-0.03-0.01-0.02-0.06-0.06-0.03-0.02-0.03-0.03-0.08

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents14.6K773.1K2.09M3.92M16.6M1.38M475.2K1.06M1.77M1.33M
Short-term investments0100.0K0
Receivables191.1K126.8K177.6K2.46K
Current assets68.4K1.14M2.35M4.16M16.8M2.16M528.3K1.09M1.90M1.35M
Property, plant and equipment1.08K1.40K1.84K2.42K3.19K4.23K5.63K5.66K7.45K
Total assets205.0K10.6M14.3M17.1M29.8M8.26M1.28M1.12M1.92M1.39M
Accounts payable2.65M2.58M2.66M3.92M436.0K210.0K199.6K213.2K237.2K
Current liabilities3.51M3.32M3.44M4.17M597.5K372.2K321.8K299.3K308.5K818.4K
Long-term debt66.9K060.0K60.0K60.0K40.0K
Total debt327.7K395.8K
Total liabilities3.66M3.40M3.60M4.46M999.7K831.5K321.8K299.3K308.5K818.4K
Shareholders' equity-3.46M7.23M10.7M12.6M28.8M7.43M960.8K821.1K1.62M568.6K
Shares outstanding425.2M418.6M357.6M321.4M318.0M199.9M72.4M58.4M53.9M32.4M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-767.7K-3.29M-6.03M-13.1M-8.31M-2.52M-1.18M-1.50M-2.08M-1.99M
Capital spending0000-3.00M0-690-1.54K-1.54K-1.50K
Free cash flow-767.7K-3.29M-6.03M-13.1M-11.3M-2.52M-1.19M-1.51M-2.08M-1.99M
Cash from investing0-2.72M142.2K-750.7K-10.9K-1.51K-1.50K
Cash from financing39.2K1.98M4.20M376.4K26.2M3.28M1.35M801.2K2.52M829.2K
Share buybacks2.02M4.20M376.1K28.7M3.39M1.35M801.2K2.65M844.7K
Change in cash-758.5K-1.31M-1.83M-12.7M15.2M906.2K-585.3K-708.2K435.4K-1.16M

Open Financials

Cap table

Built by 6ix from Revive Therapeutics Ltd.’s releases · as of Aug 14, 2026

Common shares
444,613,939
Fully diluted
472,719,870

Fully diluted

LineSharesAs of
Common shares444,613,939Jul 15, 2026
Warrants12,605,931Jul 15, 2026
Options and RSUs15,500,000Aug 14, 2026

Warrants and options

Lot
Warrants · C$0.05 · expire about Jul 2029
Warrants · C$0.05 · expire about Aug 2028
Broker warrants · C$0.05 · expiry not stated
Broker warrants · C$0.05 · expiry not stated
Stock options · C$0.05 · expire about Aug 2031

Share count over time

CountShares
Nov 22, 2026444,613,939
Jul 15, 2026443,392,423
Jun 30, 2026435,676,173

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Andrew LindzonDIRECTOR · Since at least Nov 5, 2026
Carmelo MarrelliChief Financial Officer · Since at least Nov 5, 2026
Christian ScovennaDIRECTOR · Since at least Nov 5, 2026
Joshua HermanDIRECTOR · Since at least Nov 5, 2026
Michael FrankChairman and Chief Executive Officer · Since at least Sep 15, 2026
William JacksonDIRECTOR · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Revive Therapeutics Ltd.